Anika Therapeutics Inc Stock Price, News & Analysis

Anika (Nasdaq: ANIK) reported third-quarter 2025 revenue of $27.8M, down 6% year-over-year, with Commercial Channel +22% to $12.0M and OEM Channel -20% to $15.8M. Gross margin was 56%, operating expenses were $18.8M (down 3%), loss from continuing operations was $3.2M (loss of $0.22/share), and adjusted net income was $0.7M. Cash provided by operations was $6.9M and cash balance was $58.0M. Key corporate developments: final Hyalofast PMA module filed (Oct 31, 2025) with Phase III FastTRACK data released, progress on Cingal NDA studies, J&J MedTech extended Monovisc license through Dec 2031, and a $15M 10b5-1 share repurchase planned through June 2026.

Anika Therapeutics (NASDAQ: ANIK) filed the third and final PMA module for Hyalofast with the FDA on October 31, 2025, including 24-month FastTRACK Phase III data, post-hoc analyses, and real-world evidence. The randomized FastTRACK trial did not meet its pre-specified co-primary endpoints under the original statistical plan, but post-hoc observed-data analyses showed statistically significant superiority for Hyalofast on KOOS Pain (23.37% improvement; p=0.02) and several key secondary endpoints. Responder analyses favored Hyalofast at 10-, 15-, and 20-point KOOS Pain thresholds. The company cites COVID disruptions, imbalanced dropouts, and changing standard of care as drivers of the pre-specified outcome.

Anika (NASDAQ: ANIK) will issue its third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025.

The company will hold a conference call at 8:30 a.m. ET to discuss results and business highlights; dial 1-800-717-1738 (U.S.) or 1-646-307-1865 (international) and use conference ID 53754. A live audio webcast and presentation materials will be available and archived in the Investor Relations section of www.anika.com.

Anika Therapeutics (NASDAQ: ANIK), a leader in osteoarthritis pain management and regenerative solutions, has granted inducement stock options to a new non-executive employee. The grant, made on September 2, 2025, consists of options to purchase 2,500 shares at an exercise price of $9.15 per share.

The options were granted under the company's 2021 Inducement Plan and will vest over three years, with one-third vesting annually. The options will expire after ten years and were granted as a material inducement for employment compensation, approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4).

Anika Therapeutics (NASDAQ: ANIK) reported Q2 2025 financial results with mixed performance across segments. Revenue declined 8% to $28.2 million, with Commercial Channel revenue flat and OEM Channel revenue down 13%. The company's Regenerative Solutions revenue grew 41%, driven by strong performance of the Integrity™ Implant System and Hyalofast® growth.

Key developments include Hyalofast® clinical trial results which missed primary endpoints but showed significant improvements in secondary endpoints. The company plans to file the final PMA module in H2 2025. Anika maintained its fiscal 2025 guidance but revised long-term outlook, now expecting Commercial Channel growth of 10-20% in 2026-2027, down from previous 20-30%, due to anticipated Hyalofast launch delay to 2027.

The company resolved earlier production yield issues and received FDA clearance for new Integrity implant sizes. Operating expenses decreased 17%, while Q2 resulted in a loss from continuing operations of $4.6 million ($0.33 per share).

Anika Therapeutics (NASDAQ:ANIK) has reported topline results from its FastTRACK Phase III study for Hyalofast®, a cartilage repair scaffold. While the treatment showed consistent improvements over microfracture, it missed the pre-specified co-primary endpoints for KOOS Pain and IKDC function statistical significance.

Despite this setback, Hyalofast demonstrated statistically significant improvements in secondary endpoints, including KOOS Sports and Recreation Function, Quality of Life, and Total KOOS. The product has been successfully used in over 35,000 patients across 35+ countries since 2009. Anika plans to file the final PMA module in H2 2025, incorporating additional post-hoc analyses and global data under its Breakthrough Device Designation.

Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, has scheduled its second quarter 2025 financial results announcement for Wednesday, July 30, 2025. The results will be released before market opening, followed by a conference call at 8:30 a.m. ET.

Investors can access the conference call via phone (toll-free: 1-800-717-1738 or international: 1-646-307-1865) using conference ID 48251. A live webcast and presentation materials will be available on Anika's investor relations website, with an archived version accessible after the call.

[]

Anika Therapeutics (NASDAQ: ANIK), a leader in osteoarthritis pain management and regenerative solutions, has announced inducement grants to a new non-executive employee. The company granted 2,500 non-statutory stock options at an exercise price of $10.53 per share on July 1, 2025.

The options were granted under the Anika Therapeutics 2021 Inducement Plan, with one-third of the shares vesting annually over three years, contingent on continuous service. The options will expire after ten years and were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Anika Therapeutics (NASDAQ: ANIK) announced the granting of non-statutory stock options to a newly hired non-executive employee on June 2, 2025. The options cover 2,500 shares of common stock with an exercise price of $11.45, matching the closing price on Nasdaq Global Select Market on the grant date. The options were granted under the 2021 Inducement Plan as a material inducement for employment compensation. The vesting schedule spans three years, with one-third of shares vesting annually, contingent on continuous service. The options expire after ten years and were granted without stockholder approval.